The pivotal, Phase III study will evaluate the change in average daily “OFF” time in solengepras patients compared to placebo ...

Cerevance’s attempt to unlock the first-line Parkinson's disease market has hit a snag, with solengepras performing no better ...

UK-based clinical-stage biopharmaceutical company Cerevance has announced top-line results from the Phase II ASCEND trial of solengepras as an investigational monotherapy in patients with early, ...

This investigational treatment was generally well tolerated with no serious adverse events; fewer adverse events related to non-motor symptoms were reported in the solengepras arm Pivotal Phase 3 ...

Sleep deficiency was associated with atrophy of the inferior parietal region, which is observed in early Alzheimer's disease.

Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study. The Boston-based ...

Merck is paying $25 million upfront to tap into Cerevance's NETSseq transcriptomics technology, used to discover proteins that are either over- or under-expressed in disease states, and is also ...